{"transactions":[{"id":748046,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T22:18:14.000Z","date":"2026-06-04","kind":"grant","planned":true,"acquired":true,"shares":32996,"price":6.15,"value":202925.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":32996,"derivative":{"exercise_price":6.15,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":32996},"source":{"system":"sec-edgar","filing":"0001743658-26-000002","document":"wk-form4_1780697891.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000174365826000002/wk-form4_1780697891.xml","form_type":"4"}},{"id":748045,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T22:18:14.000Z","date":"2026-06-04","kind":"grant","planned":true,"acquired":true,"shares":24193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":119193,"source":{"system":"sec-edgar","filing":"0001743658-26-000002","document":"wk-form4_1780697891.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000174365826000002/wk-form4_1780697891.xml","form_type":"4"}},{"id":748044,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T22:18:14.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":6.0943,"value":121886.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.960 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":95000,"source":{"system":"sec-edgar","filing":"0001743658-26-000002","document":"wk-form4_1780697891.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000174365826000002/wk-form4_1780697891.xml","form_type":"4"}},{"id":1067828,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T20:47:42.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":42500,"price":7.2759,"value":309225.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":115000,"source":{"system":"sec-edgar","filing":"0001867096-25-000138","document":"wk-form4_1755118058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709625000138/wk-form4_1755118058.xml","form_type":"4"}},{"id":1122977,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T23:03:38.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders."}],"balance_after":157500,"source":{"system":"sec-edgar","filing":"0001867096-25-000112","document":"wk-form4_1749078211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709625000112/wk-form4_1749078211.xml","form_type":"4"}},{"id":1490107,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:18:11.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders."}],"balance_after":107500,"source":{"system":"sec-edgar","filing":"0001867096-24-000103","document":"wk-form4_1717618682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709624000103/wk-form4_1717618682.xml","form_type":"4"}},{"id":1732766,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T21:20:16.000Z","date":"2023-11-20","kind":"purchase","planned":false,"acquired":true,"shares":5410,"price":1.84,"value":9954.4,"ownership":{"direct":false,"nature":"By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5410,"source":{"system":"sec-edgar","filing":"0001867096-23-000151","document":"wk-form4_1700601584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709623000151/wk-form4_1700601584.xml","form_type":"4"}},{"id":1863999,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-07T20:58:04.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders."}],"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001867096-23-000097","document":"wk-form4_1686171475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709623000097/wk-form4_1686171475.xml","form_type":"4"}},{"id":2237854,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:14:18.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":2.1,"exercise_date":"2022-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001867096-22-000092","document":"wf-form4_165480924524079.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709622000092/wf-form4_165480924524079.xml","form_type":"4"}},{"id":2237853,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T21:14:18.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001867096-22-000092","document":"wf-form4_165480924524079.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000186709622000092/wf-form4_165480924524079.xml","form_type":"4"}},{"id":2549130,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:51:56.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":11228,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039340/doc4.xml","form_type":"4"}},{"id":2549129,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:51:56.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":11228,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039340/doc4.xml","form_type":"4"}},{"id":2549128,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:51:56.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":20000,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-039340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039340/doc4.xml","form_type":"4"}},{"id":2549127,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:51:56.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":19650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":19650,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":19650},"source":{"system":"sec-edgar","filing":"0000899243-21-039340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039340/doc4.xml","form_type":"4"}},{"id":2549126,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:37:07.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039255/doc4.xml","form_type":"4"}},{"id":2549125,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:37:07.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039255/doc4.xml","form_type":"4"}},{"id":2549124,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:37:07.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-039255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039255/doc4.xml","form_type":"4"}},{"id":2549123,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:37:07.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":19650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":19650},"source":{"system":"sec-edgar","filing":"0000899243-21-039255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924321039255/doc4.xml","form_type":"4"}},{"id":2677782,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-08T23:09:30.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":11228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":11228,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0001346302-21-000060","document":"wf-form4_162319374400964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000134630221000060/wf-form4_162319374400964.xml","form_type":"4"}},{"id":3122267,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T01:01:00.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":11228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options will vest in full upon the earlier to occur of June 4, 2021 or the date of the Company's next annual meeting of stockholders."}],"balance_after":11228,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-20-015326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924320015326/doc4.xml","form_type":"4"}},{"id":3623412,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":40944,"kind":"person","name":"HALKUFF DAWN","position":1,"cik":"0001743658","reported_name":"HALKUFF DAWN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-01T21:39:40.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":20000,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-19-005463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743658/000089924319005463/doc4.xml","form_type":"4"}}]}